Gilead Sciences (GILD) has released an update to notify the public and investors about its officers.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
On February 1, 2024, Gilead Sciences, Inc. expanded its Board of Directors from nine to ten members and elected Ted W. Love, M.D. as a new director, with his service starting immediately. Dr. Love will also join the Audit Committee after the 2024 Annual Meeting of Stockholders, contingent upon his re-election. He has no reportable related party transactions and will receive compensation as per the standard non-employee director programs, details of which were filed with the SEC in previous reports.
For further insights into GILD corporate activity, check out TipRanks’ Insiders Trading Activity page.
For a comprehensive understanding of the announcement, you can read the full document here.